Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?
{{output}}
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field. Although there are a number of plausible explanations for this extremely high att... ...
